Advisory Services Network LLC raised its position in shares of GlaxoSmithKline plc (NYSE:GSK) by 300.0% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 16,406 shares of the pharmaceutical company’s stock after purchasing an additional 12,304 shares during the quarter. Advisory Services Network LLC’s holdings in GlaxoSmithKline were worth $582,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. First Trust Advisors LP boosted its stake in GlaxoSmithKline by 26.1% during the 4th quarter. First Trust Advisors LP now owns 619,519 shares of the pharmaceutical company’s stock valued at $21,974,000 after purchasing an additional 128,188 shares in the last quarter. Greenleaf Trust boosted its stake in GlaxoSmithKline by 672.0% during the 4th quarter. Greenleaf Trust now owns 11,094 shares of the pharmaceutical company’s stock valued at $394,000 after purchasing an additional 9,657 shares in the last quarter. Pinnacle Financial Partners Inc. boosted its stake in GlaxoSmithKline by 24.1% during the 4th quarter. Pinnacle Financial Partners Inc. now owns 15,562 shares of the pharmaceutical company’s stock valued at $552,000 after purchasing an additional 3,025 shares in the last quarter. Sei Investments Co. boosted its stake in GlaxoSmithKline by 71.6% during the 4th quarter. Sei Investments Co. now owns 577,621 shares of the pharmaceutical company’s stock valued at $20,488,000 after purchasing an additional 241,059 shares in the last quarter. Finally, Rational Advisors LLC boosted its stake in GlaxoSmithKline by 328.1% during the 4th quarter. Rational Advisors LLC now owns 65,240 shares of the pharmaceutical company’s stock valued at $2,314,000 after purchasing an additional 50,000 shares in the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.
GSK has been the subject of a number of research reports. Zacks Investment Research raised GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $40.00 price target for the company in a research note on Tuesday, January 2nd. UBS Group upgraded GlaxoSmithKline from a “neutral” rating to a “buy” rating and increased their price objective for the company from $35.04 to $35.85 in a research report on Monday, November 27th. TheStreet upgraded GlaxoSmithKline from a “c+” rating to a “b” rating in a research report on Wednesday, October 25th. Barclays upgraded GlaxoSmithKline from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, January 16th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline in a research report on Tuesday, October 24th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $38.97.
GlaxoSmithKline (NYSE:GSK) last announced its quarterly earnings data on Wednesday, February 7th. The pharmaceutical company reported $0.72 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.03. GlaxoSmithKline had a return on equity of 130.63% and a net margin of 4.97%. The company had revenue of $10.14 billion during the quarter, compared to the consensus estimate of $9.89 billion. sell-side analysts forecast that GlaxoSmithKline plc will post 2.85 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 12th. Stockholders of record on Friday, February 23rd will be issued a $0.633 dividend. The ex-dividend date of this dividend is Thursday, February 22nd. This represents a $2.53 dividend on an annualized basis and a dividend yield of 6.72%. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.50. GlaxoSmithKline’s dividend payout ratio is presently 234.48%.
TRADEMARK VIOLATION WARNING: “Advisory Services Network LLC Raises Holdings in GlaxoSmithKline plc (GSK)” was originally reported by BBNS and is the sole property of of BBNS. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://baseballnewssource.com/markets/advisory-services-network-llc-raises-holdings-in-glaxosmithkline-plc-gsk/1891201.html.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.